Global Cell and Gene Therapy Third-Party Logistics Market Size and Forecast 2025–2033

The global landscape of healthcare logistics is at a turning point, driven by the explosive growth of cell and gene therapies (CGTs)—two of the most revolutionary therapeutic categories in modern medicine. According to Renub Research, the Global Cell and Gene Therapy Third-Party Logistics Market is projected to surge from US$ 8.66 billion in 2024 to US$ 20.98 billion by 2033, expanding at a 10.33% CAGR during 2025–2033.

As the world shifts toward personalized, patient-specific medicine, logistics is no longer a back-end function—it has become a critical pillar that determines treatment feasibility, patient outcomes, and regulatory compliance.

This report-style article explores the market landscape, growth drivers, challenges, regional dynamics, and recent developments shaping the fast-evolving sector of CGT logistics.

A Market at the Crossroads of Science and Supply Chain

The Cell and Gene Therapy Third-Party Logistics (3PL) industry sits uniquely at the intersection of biotechnology innovation and high-precision supply chain management.

Unlike traditional pharmaceuticals, CGTs rely on living cells, viral vectors, and personalized biologic materials, most of which are highly temperature-sensitive and require precise handling, specialized packaging, and real-time chain-of-custody monitoring.

To meet these uncompromising requirements, logistics companies are deploying:

Cryogenic shipping technologies

Ultra-low temperature (ULT) freezers

Advanced cold chain tracking

AI-driven route optimization

Integrated data platforms for traceability and compliance

The growing pipeline of clinical trials and commercial approvals is further amplifying the need for high-precision, scalable, patient-centric logistics systems across the world.

Market Overview: Why Demand Is Rising So Rapidly

The global CGT 3PL market is witnessing rapid acceleration as advanced therapies transition from theoretical marvels to widespread clinical realities.

1. Soaring Clinical Trials and Regulatory Approvals

The number of CGT clinical studies is on the rise, with biotechnology companies conducting multi-site global trials that require specialized logistics networks. Direct-to-patient shipments, cross-border transfers of biologics, and delivery to remote trial sites all require precision handling that only specialized logistics companies can deliver.

2. Personalization Reshaping the Supply Chain

Cell and gene therapies move healthcare from mass production to patient-specific manufacturing. Each dose is customized, meaning failure in any stage—packaging, cold chain maintenance, route planning, or handling—can jeopardize the entire treatment.

3. Cross-Industry Collaboration Is Strengthening

CGT developers are increasingly partnering with logistics providers to build specialized supply chains. Many companies now co-engineer packaging, temperature-control systems, and digital traceability platforms tailored to their therapy pipelines.

Despite challenges such as regulatory complexity and the need for specialized infrastructure, the market is poised for a decade of steady, transformational growth.

Request Free Sample Report

Growth Drivers Fueling the Market

1. Rising Demand for Cell and Gene Therapies

The move toward customized, precision medicine has created unprecedented demand for cell and gene treatments. As these therapies rely on living materials highly sensitive to environmental changes, logistics becomes a mission-critical step.

Third-party logistics providers offer:

Temperature-controlled transport

Advanced tracking

Regulatory-compliant systems

Secure, sterile warehousing

As more therapies receive global approvals, the demand for high-precision logistics will accelerate dramatically.

2. Surge in Biotech Investment

Governments, investors, and pharma companies worldwide are pouring billions into:

Gene therapy platforms

CAR-T therapies

mRNA-based biologics

Rare disease treatments

These innovations require sophisticated global distribution networks. From cross-border compliance to multi-continent cold chain management, logistics providers now play a pivotal role in enabling commercialization.

3. Rise of Patient-Centric Delivery Models

The future of CGT logistics is patient-centric. Therapies are increasingly shipped directly to hospitals, clinics, or even homes, requiring:

Real-time GPS and temperature tracking

Specialized transport vehicles

Accelerated delivery capabilities

Tamper-proof packaging solutions

Logistics companies are responding with user-friendly digital tools and automated scheduling platforms that improve transparency and reduce delivery uncertainties for patients.

Key Challenges the Industry Must Overcome

Despite momentum, the CGT 3PL industry faces several obstacles that require strategic innovation.

1. Packaging and Handling Complexities

Improper handling can:

Damage sensitive biologics

Trigger contamination

Cause temperature deviation

Render a therapy ineffective or unsafe

To mitigate risks, 3PL companies are integrating:

IoT sensors

Shock and tilt indicators

Vacuum-insulated panels

Strict chain-of-identity systems

Precision is non-negotiable, as a single compromised shipment can result in treatment failure.

2. Extreme Temperature Sensitivity

Most CGTs require storage at:

–80°C to –150°C (viral vectors)

–150°C to –196°C (cryogenic cell therapies)

Maintaining these conditions across long distances is extremely challenging. Any temperature deviation can destroy the therapeutic material.

Logistics providers now rely on:

Cryogenic shippers

ULT freezers

Dry-shipper dewars

Redundant monitoring systems

Predictive analytics for route planning

Safeguarding ultra-low-temperature environments remains one of the industry's biggest hurdles.

Regional Market Dynamics

United States

The U.S. is one of the world’s most advanced CGT markets, with massive clinical trial activity and fast-developing logistics capabilities. Third-party providers offer:

FDA-compliant cold chain systems

Secure biologics storage

Patient-centric delivery models

Digitized chain-of-custody management

The U.S. market continues to expand as personalized therapies become mainstream and biotech funding grows.

Germany

Germany stands out in Europe due to:

Highly developed biopharma infrastructure

Strict regulatory frameworks

Growing CGT clinical trial activity

Regions such as Frankfurt and Düsseldorf house major biotech clusters. Leading logistics companies—UPS (Marken), Arvato, Cryoport, and AmerisourceBergen—are enhancing the market with:

Cryogenic storage

AI-driven optimization

Innovative packaging materials

Western Germany currently represents the strongest demand.

China

China’s booming biotech sector and national focus on personalized medicine are driving the CGT logistics market. Key trends include:

Large R&D investments

Widespread adoption of IoT tracking

AI-powered supply chain systems

Expanding biologics manufacturing facilities

With the government aggressively supporting biopharmaceutical innovation, China is becoming a major global CGT logistics hub.

Saudi Arabia

Under Vision 2030, Saudi Arabia aims to position itself as a biopharma powerhouse. The logistics market is benefiting from:

New cold chain infrastructure

Government–industry collaborations

Localization of gene therapy manufacturing

Adoption of advanced technologies (IoT, blockchain, AI)

As the Kingdom expands access to advanced therapies, demand for specialized 3PL services will continue to spike.

Recent Industry Developments

Cardinal Health Launches Advanced Therapy Connect (January 2025)

Cardinal Health unveiled the first unified ordering platform for cell and gene therapies—a major step toward simplifying provider access and streamlining administrative workflows.

McKesson Introduces InspiroGene (October 2024)

McKesson announced InspiroGene, a dedicated venture supporting CGT commercialization, offering:

Third-party logistics programs

Supply chain support

Expert CGT leadership guidance

Its scalable framework helps manufacturers navigate the complexities of advanced therapy distribution.

Market Segmentation Snapshot

By Type

Clinical

Commercial

By Product

Cell Therapies

Gene Therapies

By Therapeutic Area

Oncology

Neurology

Cardiovascular Diseases

Ophthalmology

Infectious Diseases

Others

By End Use

Biopharmaceutical Companies

CDMOs/CMOs

Others

Regional Coverage

North America: U.S., Canada

Europe: Germany, France, Italy, Spain, UK, Belgium, Netherlands, Turkey

Asia Pacific: China, India, Japan, Australia, South Korea, Malaysia, Indonesia, Thailand, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: UAE, Saudi Arabia, South Africa

Company Profiles Covered

Cencora Corporation

Cardinal Health

McKesson Corporation

EVERSANA

Knipper Health

Arvato SE

DHL

Kuehne+Nagel

Each company is analyzed through:

Overview | Key Persons | Recent Strategy | Revenue Analysis

Final Thoughts: Logistics Is the Backbone of the CGT Revolution

As the world moves closer to widespread adoption of curative gene therapies, regenerative treatments, and personalized cellular medicines, logistics will define the future of healthcare delivery.

The next decade will see:

Expanded cryogenic capacity

Digitized supply chains

Blockchain-based traceability

Integrated patient-centric delivery models

AI-enhanced route and temperature optimization

With the market on track to reach US$ 20.98 billion by 2033, the Cell and Gene Therapy Third-Party Logistics industry is not just supporting medical innovation—it is enabling it.

This sector will play a central role in making lifesaving advanced therapies accessible, safe, and timely for patients worldwide.